Insight Molecular Diagnostics (IMDX) Free Cash Flow (2015 - 2026)

Insight Molecular Diagnostics has reported Free Cash Flow for 12 years, with the latest figure at -$8.3 million in Q1 2026.

• Quarterly Free Cash Flow fell 34.27% year-over-year to -$8.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$27.5 million (down 16.93% YoY) and the FY2025 annual result came in at -$25.4 million, down 19.64% from the prior year.
• Free Cash Flow retreated to -$8.3 million in Q1 2026 per IMDX's latest filing, from -$7.0 million in the prior quarter.
• Over five years, Free Cash Flow peaked at -$3.2 million in Q3 2023 and troughed at -$14.8 million in Q1 2022.
• A 5-year average of -$7.5 million and a median of -$6.6 million in 2025 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2023 and 2024: Free Cash Flow soared 73.85% in 2023, then sank 75.26% in 2024.
• Over 5 years, Free Cash Flow stood at -$10.4 million in 2022, then jumped by 55.14% to -$4.7 million in 2023, then fell by 18.71% to -$5.6 million in 2024, then decreased by 26.22% to -$7.0 million in 2025, then decreased by 17.48% to -$8.3 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$8.3 million, -$7.0 million, and -$5.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.